IDEXX Laboratories, Inc. (NASDAQ:IDXX – Get Free Report) has been assigned an average rating of “Moderate Buy” from the ten analysts that are currently covering the firm, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $747.00.
A number of analysts recently weighed in on the stock. Weiss Ratings cut shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, August 27th. Wall Street Zen downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Citigroup raised their price objective on IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 5th. Barclays reduced their price objective on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a research note on Tuesday, August 11th. Finally, UBS Group boosted their target price on IDEXX Laboratories from $620.00 to $670.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 5th.
View Our Latest Stock Analysis on IDXX
Insider Buying and Selling at IDEXX Laboratories
Institutional Trading of IDEXX Laboratories
A number of hedge funds have recently bought and sold shares of the company. SHP Wealth Management acquired a new stake in shares of IDEXX Laboratories during the fourth quarter valued at approximately $26,000. Virtus Advisers LLC acquired a new position in IDEXX Laboratories in the 3rd quarter worth approximately $26,000. J.Safra Asset Management Corp acquired a new position in IDEXX Laboratories in the 2nd quarter worth approximately $25,000. Elevation Wealth Partners LLC boosted its stake in IDEXX Laboratories by 188.2% in the 2nd quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock worth $26,000 after purchasing an additional 32 shares during the period. Finally, Wormser Freres Gestion grew its position in IDEXX Laboratories by 671.4% during the 4th quarter. Wormser Freres Gestion now owns 54 shares of the company’s stock worth $37,000 after purchasing an additional 47 shares in the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.
IDEXX Laboratories Stock Performance
NASDAQ:IDXX opened at $504.70 on Thursday. IDEXX Laboratories has a twelve month low of $500.61 and a twelve month high of $769.98. The company has a current ratio of 1.17, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. The company has a 50-day moving average of $555.59 and a 200-day moving average of $566.45. The firm has a market cap of $39.76 billion, a price-to-earnings ratio of 35.49, a price-to-earnings-growth ratio of 2.69 and a beta of 1.54.
IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.94 by $0.33. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The company had revenue of $1.22 billion for the quarter, compared to analysts’ expectations of $1.20 billion. During the same quarter in the previous year, the company posted $3.50 EPS. The business’s revenue was up 9.7% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. Analysts forecast that IDEXX Laboratories will post 14.81 earnings per share for the current fiscal year.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc develops and provides diagnostic, information technology and veterinary practice-management products and services. The company primarily serves the companion animal, livestock and poultry, and water testing markets, helping customers detect, monitor and manage disease.
Its companion animal business includes in-house laboratory analyzers and consumables, reference laboratory services, diagnostic tests, veterinary software, digital imaging and related practice-management solutions.
Read More
- Five stocks we like better than IDEXX Laboratories
- Rocket Lab Tackles a Supply Chain Bottleneck as the Stock Hunts for a Bottom. Time to Buy?
- Optical Cable Corporation Is Starting to Get the Market’s Attention
- Oil Above $100 Is Creating a New Opportunity Beyond the Major Producers
- Is Nike’s Index Demotion a Warning or a Buying Opportunity?
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
